Bloodstream Infections of the Intravascular Access Devices – Case Reports and Review of the Literature
Authors:
M. Sochor 1; Z. Pelikánová 1; M. Šercl 3; V. Mellanová 3; P. P. Lazarov 1; D. Fáčková 2
Authors place of work:
Komplexní onkologické centrum, KN Liberec
1; Oddělení klinické mikrobiologie, KN Liberec
2; Radiodiagnostické oddělení, KN Liberec
3
Published in the journal:
Klin Onkol 2012; 25(5): 375-381
Category:
Case Reports
Summary
Long-term access devices (VAD) in oncology patients are the elemental procedure of contemporary treatment. Apart from their indisputable benefit they are linked with an increased risk of infectious complications, ranging between simple colonisation of a device to catheter related bloodstream infections. The decision to salvage or extract the VAD in case of bloodstream infection depends on patient´s clinical state, localisation of infection (site of insertion, catheter or pocket), casual agent and complications (e.g. endocarditis, septic embolization, osteomyelitis and so on). Authors present 5 case reports of portacath sepsis in their oncology department in 2011 (i.e. 4.46% of 112 inserted ports). In the second part of the article they review current literature data about prevention and treatment of infectious complications of vascular devices in cancer patients.
Key words:
vascular access devices – catherer-related infections – prevention and treatment – oncology
Submitted:
29. 2. 2012
Accepted:
3. 5. 2012
Zdroje
1. US Renal Data System. Excerpts from the USRDS annual data report: atlas of end-stage renal disease in the United States: clinical indicators of care. Am J Kidney Dis 2001; 4 (Suppl 3): S79–S90.
2. Camp-Sorrell D. State of the science of oncology vascular access devices. Semin Oncol Nurs 2010; 26(2): 80–87.
3. Gallieni M, Pittiruti M, Biffi R. Vascular access in oncology patients. CA Cancer J Clin 2008; 58(6): 323–346.
4. Raad II, Hanna HA. Intravascular catheter-related infections: new horizons and recent advances. Arch Intern Med 2002; 162(8): 871–878.
5. Crnich CJ, Maki DG. The role of intravascular devices in sepsis. Curr Infect Dis Rep 2001; 36): 496–506.
6. Crnich CJ, Maki DG. Infections caused by intravscular devices: epidemiology, pathogenesis, diagnosis, prevention and treatment. In: APIC Text of Infection Control and Epidemiology. Vol 1. 2nd ed. Washington: Association for Professionals in Infection Control and Epidemiology, Inc 2005: 24.21–24.26.
7. Blot SI, Depuydt P, Annemans L et al. Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin Infect Dis 2005; 41(11): 1591–1598.
8. Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc 2006; 81(9): 1159–1171.
9. Wisplinghoff H, Seifert H, Wenzel RP et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36(9): 1103–1110.
10. Groeger JS, Lucas AB, Thaler HT et al. Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 1993; 119(12): 1168–1174.
11. Vescia S, Baumgärtner AK, Jacobs VR et al. Management of venous port systems in oncology: a review of current evidence. Ann Oncol 2008; 19(1): 9–15.
12. Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49(1): 1–45.
13. Mermel LA, Farr BM, Sherertz RJ et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32(9): 1249–1272.
14. Murphy C, Andrus M, Barnes S et al. Guide to the elimination of catheter-related bloodstream infections. Washington: Association for Professionals in Infection Control and Epidemiology, Inc 2009.
15. Pearson ML. Guideline for prevention of intravascular device-related infections. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996; 17(7): 438–473.
16. O’Grady NP, Alexander M, Delinger EP et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002; 51(RR–10): 1–29.
17. Fowler VG Jr, Justice A, Moore C et al. Risk factors for hematogenous complications of intravascular catheter--associated Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40(5): 695–703.
18. Chatzinikolaou I, Hanna H, Hachem R et al. Differential quantitative blood cultures for the diagnosis of catheter--related bloodstream infections associated with short- and long-term catheters: a prospective study. Diagn Microbiol Infect Dis 2004; 50(3): 167–172.
19. Pigrau C, Rodríguez D, Planes AM et al. Management of catheter-related Staphylococcus aureus bacteremia: when may sonographic study be unnecessary. Eur J Clin Microbiol Infect Dis 2003; 22(12): 713–719.
20. Fernandez-Hidalgo N, Almirante B, Calleja R et al. Antibiotic-lock therapy for long-term intravscular catheter-related bacteraemia: results of an open, non-comparative study. J Antimicrob Chemother 2006; 57(6): 1172–1180.
21. Fortún J, Grill F, Martín-Dávila P et al. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic-lock therapy. J Antimicrob Chemother 2006; 58(4): 816–821.
22. Raad I, Davis S, Khan A et al. Impact of central venous catheter removal on the recurrence of catheter-related coagulase-negative staphylococcal bacteremia. Infect Control Hosp Epidemiol 1992; 13(4): 215–221.
23. Rijnders BJ, Van Wijngaerden E, Vandecasteele SJ et al. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. J Antimicrob Chemother 2005; 55(1): 90–94.
24. Guggenbichler JP, Berchtold D, Allerberger F et al. In vitro and in vivo effect of antibiotics on catheter colonized by staphylococci. Eur J Clin Microbiol Infect Dis 1992; 11(5): 408–415.
25. Pascual A, Ramirez de Arellano E, Martínez Martínez L et al. Effect of polyurethane catheters and bacterial biofilms on the in-vitro activity of antimicrobials against Staphylococcus epidermidis. J Hosp Infect 1993; 24(3): 211–218.
26. Safdar N, Mermel LA, Maki DG. The epidemiology of catheter-related infection in the critically ill. In: O’Grady N, Pitter D (eds). Catheter-related infections in the critically ill. New York: Kluwer 2004: 1–23.
27. Safdar N, Fine JP, Maki DG. Meta-analysis: methods for diagnosing intravascular device-related bloodstream infection. Ann Intern Med 2005; 142(6): 451–466.
28. Stevens M, Bearman G, Edmond M. Development of an improved surveillance definition for central line associated bloodstream infection. In: SHEA 2009. San Diego: the Society for Healthcare Epidemiology of America, 19th Annual Scientific Meeting. March 19–22, 2009.
29. Rijnders BJ, Vandecasteele SJ, Van Wijngaerden E et al. Use of semiautomatic treatment advice to improve compliance with Infectious Diseases Society of America guidelines for treatment of intravascular catheter-related infection: a before-after study. Clin Infect Dis 2003; 37(7): 980–983.
Štítky
Paediatric clinical oncology Surgery Clinical oncologyČlánok vyšiel v časopise
Clinical Oncology
2012 Číslo 5
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
- Spasmolytic Effect of Metamizole
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- Uterine Sarcomas – a Review
- Analysis of Prognostic Factors in Osteosarcoma Adult Patients, a Single Institution Experience
- Bloodstream Infections of the Intravascular Access Devices – Case Reports and Review of the Literature
- BRAF Mutation: a Novel Approach in Targeted Melanoma Therapy